SIDE-BY-SIDE EVIDENCE
Compare evidence.
Keep the context.
Select 2–3 profiles from the English Library. Class and grade describe evidence and regulatory context, not comparative effectiveness or suitability for an individual.
Choose profilesSIDE-BY-SIDE EVIDENCE VIEW
Compare selected profiles
| Molecule |  Clomiphene citrate | Enclomiphene / Enclomifene | Tamoxifen |
|---|---|---|---|
| Research Topic | Clinical / Endocrine Pharmacology | Reproductive Endocrinology | Clinical / Endocrine Pharmacology |
| Pharmacology | Selective estrogen receptor modulator medicine | Selective estrogen receptor modulator / clomiphene isomer | Selective estrogen receptor modulator medicine |
| PrimeCore Class | Class AApproved in a bounded context | Class BInvestigational | Class AApproved in a bounded context |
| Evidence Grade | Grade AStrong regulatory + clinical evidence | Grade CEarly human evidence | Grade AStrong regulatory + clinical evidence |
| Evidence boundary | Clomiphene citrate is classified here as Selective estrogen receptor modulator medicine. Prescription labels support bounded ovulatory-dysfunction use; off-label endocrine use is not equivalent to an approved indication. U.S. prescription labels exist for defined female infertility contexts; WADA prohibits clomifene at all times under hormone and metabolic modulators. A catalogue name does not establish identity, formulation, quality or authorisation, and this page provides no dosage, mixing, injection or purchasing instructions. | Enclomiphene is a clomiphene isomer, not testosterone or the full clomiphene mixture. Trials reported hormone and sperm-count effects, but these do not establish symptom or live-birth benefit. EMA refused EnCyzix in 2018, citing insufficient symptom evidence and venous-thromboembolism concerns. | Tamoxifen is classified here as Selective estrogen receptor modulator medicine. Large controlled oncology evidence supports product-specific breast-cancer indications and prevention contexts. FDA-authorised prescription products exist for defined oncology contexts; WADA prohibits SERMs at all times. A catalogue name does not establish identity, formulation, quality or authorisation, and this page provides no dosage, mixing, injection or purchasing instructions. |
| Unknowns | Insufficient data in the current dataset | Insufficient data in the current dataset | Insufficient data in the current dataset |
| Limitations |
| English translation is not yet verified for 1 excerpt(s). This is a language gap, not an absence of risks or uncertainty. Read original excerpts (Thai / mixed language)
|
|
| Sources | |||
| Read more | Read English overview | Read English overview | Read English overview |
This table does not compare doses, cross-trial outcomes or individual suitability. Missing information does not establish an absence of risk.
Choose another comparisonContinue reading
Missing fields mean information is unavailable in the current structured dataset, not that a molecule has no risks or uncertainties. English translations retain the original evidence boundaries. Where translation is not yet verified, the original Thai excerpts remain available under an explicit label. Sources retain their original language.
10 questions before drawing conclusions